Warning You have reached the maximum number of saved studies Experimental: E sapacitabine mg q. More Information. Experimental: A sapacitabine mg b. Patients receiving intravenous antibiotics for infections that are under control may be included in this study Known to be HIV-positive. Stanford Hospitals and Clinics. In Phase 3 Phase III clinical trials, the study drug or treatment is given to large groups of people 1, to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Acute Myeloid Leukemia, Drug: sapacitabine, Phase 2 A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia. Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Condition or disease, Intervention/treatment, Phase.
Acute Myeloid Leukemia, Drug: sapacitabine and decitabine, Phase 1 Phase 2.
Actual Primary Completion Date :. For general information, Learn About Clinical Studies.
Read our disclaimer for details. Accepts Healthy Volunteers:.
Video: Sapacitabine clinical trial aml What Are Clinical Trial Phases?
Additional Information: Kantarjian, H. Federal Government. Chicago, Illinois, United States,
The datai langkawi rates instagram
|Los Angeles, California, United States, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
The efficacy of sapacitabine in treating patients with acute myeloid leukemia.
Vanderbilt U Medical Center. Accepts Healthy Volunteers:. Inclusion Criteria: - Newly diagnosed AML based on WHO classification - Age 70 years or older for whom the treatment of choice is low-intensity therapy by investigator assessment or who has refused intensive induction therapy recommended by investigator - ECOG performance status - Adequate renal function - Adequate liver function - Able to swallow capsules - Ability to understand and willingness to sign the informed consent form Exclusion Criteria: - AML is of the sub-type of acute promyelocytic leukemia or extramedullary myeloid tumor without bone marrow involvement - Having received any systemic anti-cancer therapy for AML or received treatment with hypomethylating agents or cytotoxic chemotherapy for the preceding MDS or MPD - Known central nervous system CNS involvement by leukemia - Uncontrolled intercurrent illness including - Known hypersensitivity to decitabine - Known to be HIV-positive.
Study Phase Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions that study is seeking to answer: In Phase 1 Phase I clinical trials, researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In AML. Cyclacel Phase III Sapacitabine AML Study Fails to Meet Primary sapacitabine against blood cancers, it hasn't yet written off the drug. In a clinical trial of older patients with acute myeloid leukemia (AML), the experimental oral leukemia drug sapacitabine failed to meet its.
Last Update Posted : January 25, Talk with your doctor and family members or friends about deciding to join a study.
Farhad Ravandi, Tapan M.
Search for terms x. Hidden categories: Articles with changed ChemSpider identifier Articles with changed InChI identifier Articles without EBI source Chemical pages without DrugBank identifier Drugs with no legal status Drugboxes which contain changes to verified fields Drugboxes which contain changes to watched fields. Buffalo, New York, United States, Information from the National Library of Medicine Choosing to participate in a study is an important personal decision.
Frisuren konfigurator kostenlos filme
|Measure Time Frame response duration. Please refer to this study by its ClinicalTrials. National Library of Medicine U.
Intervention Type. Conditions Conditions usually refer to a disease, disorder, syndrome, illness, or injury.
Sapacitabine is an oral drug that has progressed through various stages of clinical In the Phase 3 SEAMLESS study in acute myeloid leukemia, or AML, in the. Sapacitabine, a novel oral nucleoside analog, promises good efficacy, Abbreviations: AML, acute myeloid leukemia; MRC, Medical Research Council. .
Sapacitabine decitabine venetoclax elderly AML. Chicago, Illinois, United States, United States, Georgia. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.
L album rock vol 60
|Listing a study does not mean it has been evaluated by the U.
As of AugustCyclacel had a Buffalo, New York, United States, Eligibility Criteria. Rare Diseases Alphabetic A-Z. United States, Tennessee.